

MAP3K13 (LZK) Antibody

Mouse Monoclonal Antibody (Mab)
Catalog # AM9976b

Specification

MAP3K13 (LZK) Antibody - Product Information

Application WB, IF,E
Primary Accession O43283
Reactivity Human
Host Mouse
Clonality Monoclonal
Isotype IgM

Isotype IgM
Antigen Region 52-305

MAP3K13 (LZK) Antibody - Additional Information

Gene ID 9175

Other Names

Mitogen-activated protein kinase kinase kinase 13, Leucine zipper-bearing kinase, Mixed lineage kinase, MLK, MAP3K13 (HGNC:6852)

Target/Specificity

Purified His-tagged MAP3K13 protein fragment was used to produced this monoclonal antibody.

Dilution

WB~~1:500 IF~~1:100

E~~Use at an assay dependent concentration.

Format

Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

MAP3K13 (LZK) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

MAP3K13 (LZK) Antibody - Protein Information

Name MAP3K13 (<u>HGNC:6852</u>)





Function Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB- containing complex that phosphorylates inhibitors of NF-kappa-B.

Cellular Location

Cytoplasm. Membrane; Peripheral membrane protein

Tissue Location


Expressed in the adult brain, liver, placenta and pancreas, with expression strongest in the pancreas

MAP3K13 (LZK) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

MAP3K13 (LZK) Antibody - Images




Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green). DAPI was used to stain the cell nuclear (blue).






Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green).



Fluorescent image of NCI-H460 cells stained with MAP3K13 (LZK) Antibody (Cat#AP9976b). AP9976b was diluted at 1:100 dilution. An Alexa Fluor® 488-conjugated goat anti-mouse IgM at 1:400 dilution was used as the secondary antibody (green). DAPI was used to stain the cell nuclear (blue). Cytoplasmic actin was counterstained with Alexa Fluor® 555 conjugated with Phalloidin (red).





Anti-MAP3K13 (LZK) Antibody at 1:500 dilution + NCI-H460 whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-mouse IgM, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 110 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

MAP3K13 (LZK) Antibody - Background

Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

MAP3K13 (LZK) Antibody - References

Ikeda A., et al. J. Biochem. 130:773-781(2001). Masaki M., et al. Eur. J. Biochem. 270:76-83(2003). Greenman C., et al. Nature 446:153-158(2007). Sakuma H., et al. J. Biol. Chem. 272:28622-28629(1997). Ota T., et al. Nat. Genet. 36:40-45(2004).